2xix Citations

A crystallographic fragment screen identifies cinnamic acid derivatives as starting points for potent Pim-1 inhibitors.

Acta Crystallogr D Biol Crystallogr 67 156-66 (2011)
Related entries: 2xiy, 2xiz, 2xj0, 2xj1, 2xj2

Cited: 7 times
EuropePMC logo PMID: 21358046

Abstract

A crystallographic fragment screen was carried out to identify starting points for the development of inhibitors of protein kinase Pim-1, a potential target for tumour therapy. All fragment hits identified via soaking in this study turned out to bind to the unusually hydrophobic pocket at the hinge region. The most potent fragments, two cinnamic acid derivatives (with a best IC(50) of 130 µM), additionally form a well defined hydrogen bond. The balance between hydrophobic and polar interactions makes these molecules good starting points for further optimization. Pim-2 inhibitors from a recently reported high-throughput screening campaign also feature a cinnamic acid moiety. Two of these Pim-2 inhibitors were synthesized, their potencies against Pim-1 were determined and their cocrystal structures were elucidated in order to determine to what degree the binding modes identified by fragment screening are conserved in optimized inhibitors. The structures show that the cinnamic acid moieties indeed adopt the same binding mode. Fragment screening thus correctly identified binding modes which are maintained when fragments are grown into larger and higher affinity inhibitors. The high-throughput screening-derived compound (E)-3-{3-[6-(4-aminocyclohexylamino)-pyrazin-2-yl]phenyl}acrylic acid (compound 1) is the most potent inhibitor of the cinnamic acid series for which the three-dimensional binding mode is known (IC(50) = 17 nM, K(d) = 28 nM). The structure reveals the molecular basis for the large gain in potency between the initial fragment hit and this optimized inhibitor.

Articles - 2xix mentioned but not cited (2)

  1. Identification of the first inhibitor of the GBP1:PIM1 interaction. Implications for the development of a new class of anticancer agents against paclitaxel resistant cancer cells. Andreoli M, Persico M, Kumar A, Orteca N, Kumar V, Pepe A, Mahalingam S, Alegria AE, Petrella L, Sevciunaite L, Camperchioli A, Mariani M, Di Dato A, Novellino E, Scambia G, Malhotra SV, Ferlini C, Fattorusso C. J Med Chem 57 7916-7932 (2014)
  2. Efficacy and Toxicity Assessment of Different Antibody Based Antiangiogenic Drugs by Computational Docking Method. Mukherjee S, Chatterjee G, Ghosh M, Das B, Majumder D. Adv Bioinformatics 2016 7053712 (2016)


Reviews citing this publication (1)

  1. Targeting Pim kinases for cancer treatment: opportunities and challenges. Le BT, Kumarasiri M, Adams JR, Yu M, Milne R, Sykes MJ, Wang S. Future Med Chem 7 35-53 (2015)

Articles citing this publication (4)

  1. Computational interaction analysis of organophosphorus pesticides with different metabolic proteins in humans. Sharma AK, Gaur K, Tiwari RK, Gaur MS. J Biomed Res 25 335-347 (2011)
  2. Crystal structure of pim1 kinase in complex with a pyrido[4,3-d]pyrimidine derivative suggests a unique binding mode. Lee SJ, Han BG, Cho JW, Choi JS, Lee J, Song HJ, Koh JS, Lee BI. PLoS One 8 e70358 (2013)
  3. Identification of quinones as novel PIM1 kinase inhibitors. Schroeder RL, Goyal N, Bratton M, Townley I, Pham NA, Tram P, Stone T, Geathers J, Nguyen K, Sridhar J. Bioorg Med Chem Lett 26 3187-3191 (2016)
  4. QSAR studies on PIM1 and PIM2 inhibitors using statistical methods: a rustic strategy to screen for 5-(1H-indol-5-yl)-1,3,4-thiadiazol analogues and predict their PIM inhibitory activity. Aouidate A, Ghaleb A, Ghamali M, Chtita S, Choukrad M, Sbai A, Bouachrine M, Lakhlifi T. Chem Cent J 11 41 (2017)